871224-68-9

Basic information

• Product Name: (S)-2-(METHYLAMINO)-2-OXO-1-PHENYLETHYL 4-METHYLBENZENESULFONATE
• Synonyms: (S)-2-(METHYLAMINO)-2-OXO-1-PHENYLETHYL 4-METHYLBENZENESULFONATE;4-Methylbenzenesulfonic acid 2-(methylamino)-2-oxo-1(S)-phenylethyl ester
• CAS NO: 871224-68-9
• Molecular Formula: C₁₆H₁₇NO₄S
• Molecular Weight: 319.38
• Mol File: 871224-68-9.mol

Chemical Properties

• Boiling Point: 547.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.256±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.83±0.46(Predicted)
• CAS DataBase Reference: (S)-2-(METHYLAMINO)-2-OXO-1-PHENYLETHYL 4-METHYLBENZENESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(METHYLAMINO)-2-OXO-1-PHENYLETHYL 4-METHYLBENZENESULFONATE(871224-68-9)
• EPA Substance Registry System: (S)-2-(METHYLAMINO)-2-OXO-1-PHENYLETHYL 4-METHYLBENZENESULFONATE(871224-68-9)

Safety Data

• Hazardous Substances Data: 871224-68-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(S)-2-(METHYLAMINO)-2-OXO-1-PHENYLETHYL 4-METHYLBENZENESULFONATE is used as a reagent in organic synthesis for its ability to facilitate various chemical reactions and contribute to the formation of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (S)-2-(METHYLAMINO)-2-OXO-1-PHENYLETHYL 4-METHYLBENZENESULFONATE is utilized as a reagent in the development and synthesis of new drugs. Its potential medicinal properties make it a valuable building block in the creation of biologically active compounds.
Used in the Synthesis of Biologically Active Compounds:
(S)-2-(METHYLAMINO)-2-OXO-1-PHENYLETHYL 4-METHYLBENZENESULFONATE is employed as a key intermediate in the synthesis of various biologically active compounds, owing to its unique structure and properties that can be further modified to achieve desired therapeutic effects.

Upstream product

• 21210-43-5 (S)-Methyl mandelate 
• 65645-88-7 (S)-α-hydroxy-N-methyl-2-phenylacetamide 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 913358-93-7 almorexant hydrochloride 
• 1446238-96-5 (R)-2-((S)-6,7-dimethoxy-1-(4-(trifluoromethyl)styryl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide 
• 1036401-40-7 (R)-2'-{1-chloro-3-ethyl-(S)-8-[2-(4-trifluoromethylphenyl)ethyl]-5,6-dihydro-8H-imidazo[1,5-a]pyrazin-7-yl}-N-methyl-2'-phenylacetamide 
• 1202689-54-0 (R)-2'-{1-chloro-3-cyclopropyl-(S)-8-[2-(4-difluoromethoxy-3-fluoro-phenyl)-ethyl]-5,6-dihydro-8H-imidazo[1,5-a]pyrazin-7-yl}-N-methyl-2'-phenyl-acetamide 
• 1202689-75-5 (R)-2'-{1-chloro-3-cyclopropyl-(S)-8-[2-(2-fluoro-4-trifluoromethyl-phenyl)-ethyl]-5,6-dihydro-8H-imidazo[1,5-a]pyrazin-7-yl}-N-methyl-2'-phenyl-acetamide 
• 1202689-49-3 (R)-2'-{1-chloro-3-cyclopropyl-(S)-8-[2-(3-fluoro-4-trifluoromethyl-phenyl)-ethyl]-5,6-dihydro-8H-imidazo[1,5-a]pyrazin-7-yl}-N-methyl-2'-phenyl-acetamide 
• 1202689-74-4 (R)-2'-{1-chloro-3-cyclopropyl-(S)-8-[2-(3-trifluoromethyl-phenyl)-ethyl]-5,6-dihydro-8H-imidazo[1,5-a]pyrazin-7-yl}-N-methyl-2'-phenyl-acetamide 
• 1202689-73-3 (R)-2'-{1-chloro-3-cyclopropyl-(S)-8-[2-(4-trifluoromethyl-phenyl)-ethyl]-5,6-dihydro-8H-imidazo[1,5-a]pyrazin-7-yl}-N-methyl-2'-phenyl-acetamide 
• 1444470-29-4 C₂₆H₂₇ClF₄N₄O 
• 1444470-25-0 C₂₆H₂₇ClF₄N₄O 
• 1444470-21-6 C₂₅H₂₆ClF₃N₄O 
• 1036401-42-9 (R)-2'-{1-chloro-(S)-8-[2-(3,5-difluoro-4-trifluoromethylphenyl)ethyl]-3-ethyl-5,6-dihydro-8H-imidazo[1,5-a]pyrazin-7-yl}-N-methyl-2'-phenylacetamide 
• 1036402-20-6 (R)-2'-{1-chloro-(S)-8-[2-(2,5-difluoro-4-trifluoromethylphenyl)ethyl]-3-ethyl-5,6-dihydro-8H-imidazo[1,5-a]pyrazin-7-yl}-N-methyl-2'-phenylacetamide 
• 1444470-12-5 C₂₆H₂₆ClF₅N₄O 

Relevant articles and documents

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I) wherein R1, R2, R3, and R4 are as described n the description, to salts, especially pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments; especially as orexin receptor antagonists.

TRISUBSTITUTED 3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUND, PROCESS FOR ITS PREPARATION, AND ITS USE

The present invention relates to the compound of formula 7*acetate (see below), a process for its preparation, and its use

PROCESS FOR THE PREPARATION OF AN ENANTIOMERIC TRISUBSTITUTED 3,4-DIHYDRO-ISOQUINOLINE DERIVATIVE

The present invention relates to a process for the preparation of the compound of formula (7) which process comprises the hydrogenation of the compound of formula (4) using bis[chloro-1,5-cyclooctadiene-iridium], (S)-i-dicyclohexylphosphino-2-[(S)-α-(dime

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5- a]pyrazine derivatives of formula (I) wherein R1, R2, R3, and R4 are as described n the description, to salts, especially pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments; especially as orexin receptor antagonists.

PROCESS FOR THE PREPARATION OF AN ENANTIOMERIC TRISUBSTITUTED 3,4-DIHYDRO-ISOQUINOLINE DERIVATIVE

The present invention relates to a process for the preparation of the compound of formula (7) which process comprises the hydrogenation of the compound of formula (4) using bis[chloro-1,5-cyclooctadiene-iridium], (S)-i -dicyclohexylphosphino- 2-[(S)-α-(di

TRISUBSTITUTED 3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUND, PROCESS FOR ITS PREPARATION, AND ITS USE

The present invention relates to the compound of formula (7*)acetate (see below), a process for its preparation, and its use.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.

SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES

The invention relates to novel 1,2,3,4-tetrahydroisoquinoline derivatives of formula (I) wherein R1, R2, R3 and X are as defined in the claims, and their use as active ingredients in the preparation of pharmaceutical compo